Jasper Therapeutics, Inc. JSPR

Jasper Therapeutics Inc. (NASDAQ:JSPR) reported better-than-expected second-quarter 2026 results on Monday, although shares of the clinical-stage biotechnology company fell 4.

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders Completed a concurrent PIPE financing raising $132 million in gross proceeds REDWOOD CITY, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders Concurrent $132 million private investment with participation from leading life sciences investors and Mirador Therapeutics Kira out-licenses KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small molecule C5a receptor antagonist, to Mirador Therapeutics, for $12 million upon signing and potential development and sales milest

Recently published Chronic Spontaneous Urticaria Market Insights report includes a comprehensive understanding of current treatment practices, chronic spontaneous urticaria emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensi

REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update. "In recent months, we have continued

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the 8 Most Oversold Penny Stocks to Buy Right Now. On April 1, 2026, Evercore ISI lowered the price target on Jasper Therapeutics, Inc. (NASDAQ:JSPR) to $7 from $12 and maintained an Outperform rating. Evercore ISI said the adjustment reflects updates across its small-to-mid cap biotechnology coverage as […]

REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2025 and provided a corporate update. "Briquilimab has demons

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the penny stocks with the potential to rise 1000 percent. UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a $1.50 price target, arguing that competition in the space could limit upside. The note also said investors likely want to see longer-term […]